The Brominated Compound Aeroplysinin-1 Inhibits Proliferation and the Expression of Key Pro- Inflammatory Molecules in Human Endothelial and Monocyte Cells

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Martínez Poveda, Beatriz ^a   García Vilas, Javier A ^a   Cárdenas, Casimiro ^a   Melgarejo, Esther ^a   Quesada, Ana R ^a,b   Medina, Miguel A ^a,b  

^a UNIVERSITY OF MÁLAGA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AEROPLYSININ 1; ANGIOGENESIS INHIBITOR; CELL PROTEIN; CYCLOOXYGENASE 2; EGF LATROPHILIN AND SEVEN TRANSMEMBRANE DOMAIN CONTAINING PROTEIN 1; INTERLEUKIN 1ALPHA; INTERSTITIAL COLLAGENASE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; THROMBOSPONDIN 1; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; INHIBITION KINETICS; MOLECULAR MODEL; MONOCYTE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING;

ACETONITRILES; ANGIOGENESIS INHIBITORS; ANIMALS; CELL PROLIFERATION; CHEMOKINE CCL2; CYCLOHEXENES; CYCLOOXYGENASE 2 INHIBITORS; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INHIBITORY CONCENTRATION 50; MONOCYTES; PORIFERA; TETRAZOLIUM SALTS; THIAZOLES; THROMBOSPONDIN 1;

EID: 84873879005     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055203     Document Type: Article

References (43)

1. Fattorusso E, Minale L, Sodano G, (1972) Aeroplysinin-1, an antibacterial bromo-compound from the sponge Verongia aerophoba. J Chem Soc Perkin 1 1: 16-18.
2. Debitus C, Guella G, Mancini II, Waikedre J, Guemas JP, et al. (1998) Quinolones from a bacterium and tyrosine metabolites from its host sponge, Suberea creba from the Coral Sea. J Mar Biotechnol 6: 136-141.
3. Thoms C, Wolff M, Padmakumar K, Ebel R, Proksch P, (2004) Chemical defense of Mediterranean sponges Aplysina cavernicola and Aplysina aerophoba. Z Naturforsch C 59: 113-122.
4. Thoms C, Ebel R, Proksch P, (2006) Activated chemical defense in aplysina sponges revisited. J Chem Ecol 32: 97-123.
5. Nieder M, Hager L, (1985) Conversion of alpha-amino acids and peptides to nitriles and aldehydes by bromoperoxidase. Arch Biochem Biophys 240: 121-127.
6. Hinterding K, Knebel A, Herrlich P, Waldmann H, (1998) Synthesis and biological evaluation of aeroplysinin analogues: a new class of receptor tyrosine kinase inhibitors. Bioorg Med Chem 6: 1153-1162.
7. Teeyapant R, Woerdenbag HJ, Kreis P, Hacker J, Wray V, et al. (1993) Antibiotic and cytotoxic activity of brominated compounds from the marine sponge Verongia aerophoba. Z Naturforsch C 48: 939-945.
8. Kreuter MH, Bernd A, Holzmann H, Muller-Klieser W, Maidhof A, et al. (1989) Cytostatic activity of aeroplysinin-1 against lymphoma and epithelioma cells. Z Naturforsch C 44: 680-688.
9. Kreuter MH, Leake RE, Rinaldi F, Muller-Klieser W, Maidhof A, et al. (1990) Inhibition of intrinsic protein tyrosine kinase activity of EGF-receptor kinase complex from human breast cancer cells by the marine sponge metabolite (+)-aeroplysinin-1. Comp Biochem Physiol B 97: 151-158.
10. Kreuter MH, Robitzki A, Chang S, Steffen R, Michaelis M, et al. (1992) Production of the cytostatic agent aeroplysinin by the sponge Verongia aerophoba in in vitro culture. Comp Biochem Physiol C 101: 183-187.
11. Koulman A, Proksch P, Ebel R, Beekman AC, van Uden W, et al. (1996) Cytotoxicity and mode of action of aeroplysinin-1 and a related dienonefrom the sponge Aplysina aerophoba. J Nat Prod 59: 591-594.
12. Rodríguez-Nieto S, González-Iriarte M, Carmona R, Muñoz-Chápuli R, Medina MA, et al. (2002) Antiangiogenic activity of aeroplysinin-1, a brominated compound isolated from a marine sponge. Faseb J 16: 261-263.
13. Auerbach R, Lewis R, Shinners B, Kubai L, Akhtar N, (2003) Angiogenesis assays: a critical overview. Clin Chem 49: 32-40.
14. Staton CA, Reed MW, Brown NJ, (2009) A critical analysis of current in vitro and in vivo angiogenesis assays. Int J Exp Pathol 90: 195-221.
15. Niu QX, Chen HQ, Chen ZY, Fu YL, Lin JL, et al. (2008) Induction of inflammatory cytokine release from human umbilical vein endothelial cells by agonists of proteinase-activated receptor-2. Clin Exp Pharmacol Physiol 35: 89-96.
16. Subbaramaiah K, Dannenberg AJ, (2003) Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 24: 96-102.
17. Simmons DL, Botting RM, Hla T, (2004) Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 56: 387-437.
18. Cipollone F, Fazia ML, (2006) COX-2 and atherosclerosis. J Cardiovasc Pharmacol 47Suppl 1: S26-36.
19. Cárdenas C, Quesada AR, Medina MA, (2011) Anti-angiogenic and anti-inflammatory properties of kahweol, a coffee diterpene. PLoS One 6: e23407.
20. Garcia-Caballero M, Mari-Beffa M, Medina MA, Quesada AR, (2011) Dimethylfumarate inhibits angiogenesis in vitro and in vivo: a possible role for its antipsoriatic effect? J Invest Dermatol 131: 1347-1355.
21. Adams JC, (2001) Thrombospondins: multifunctional regulators of cell interactions. Annu Rev Cell Dev Biol 17: 25-51.
22. Narizhneva NV, Razorenova OV, Podrez EA, Chen J, Chandrasekharan UM, et al. (2005) Thrombospondin-1 up-regulates expression of cell adhesion molecules and promotes monocyte binding to endothelium. FASEB J 19: 1158-1160.
23. Zhou X, Huang J, Chen J, Zhao J, Ge D, et al. (2004) Genetic association analysis of myocardial infarction with thrombospondin-1 N700S variant in a Chinese population. Thromb Res 113: 181-186.
24. Forslow A, Liu Z, Sundqvist KG, (2007) Receptor communication within the lymphocyte plasma membrane: a role for the thrombospondin family of matricellular proteins. Cell Mol Life Sci 64: 66-76.
25. Conti P, DiGioacchino M, (2001) MCP-1 and RANTES are mediators of acute and chronic inflammation. Allergy Asthma Proc 22: 133-137.
26. Yu JL, Rak JW, (2003) Host microenvironment in breast cancer development: inflammatory and immune cells in tumour angiogenesis and arteriogenesis. Breast Cancer Res 5: 83-88.
27. Ikeda U, Matsui K, Murakami Y, Shimada K, (2002) Monocyte chemoattractant protein-1 and coronary artery disease. Clin Cardiol 25: 143-147.
28. Melgarejo E, Medina MA, Sánchez-Jiménez F, Botana LM, Domínguez M, et al. (2007) (-)-Epigallocatechin-3-gallate interferes with mast cell adhesiveness, migration and its potential to recruit monocytes. Cell Mol Life Sci 64: 2690-2701.
29. Melgarejo E, Medina MA, Sánchez-Jiménez F, Urdiales JL, (2009) Epigallocatechin gallate reduces human monocyte mobility and adhesion in vitro. Br J Pharmacol 158: 1705-1712.
30. Scarborough RM, (2003) Protease-activated receptor-2 antagonists and agonists. Curr Med Chem Cardiovasc Hematol Agents 1: 73-82.
31. Ossovskaya VS, Bunnett NW, (2004) Protease-activated receptors: contribution to physiology and disease. Physiol Rev 84: 579-621.
32. Nechiporuk T, Urness LD, Keating MT, (2001) ETL, a novel seven-transmembrane receptor that is developmentally regulated in the heart. ETL is a member of the secretin family and belongs to the epidermal growth factor-seven-transmembrane subfamily. J Biol Chem 276: 4150-4157.
33. Porto Neto LR, Bunch RJ, Harrison BE, Barendse W, (2011) DNA variation in the gene ELTD1 is associated with tick burden in cattle. Anim Genet 42: 50-55.
34. Lee KT, Byun MJ, Kang KS, Park EW, Lee SH, et al. (2011) Neuronal genes for subcutaneous fat thickness in human and pig are identified by local genomic sequencing and combined SNP association study. PLoS One 6: e16356.
35. Herouy Y, Mellios P, Bandemir E, Dichmann S, Nockowski P, et al. (2001) Inflammation in stasis dermatitis upregulates MMP-1, MMP-2 and MMP-13 expression. J Dermatol Sci 25: 198-205.
36. Li D, Williams V, Liu L, Chen H, Sawamura T, et al. (2002) LOX-1 inhibition in myocardial ischemia-reperfusion injury: modulation of MMP-1 and inflammation. Am J Physiol Heart Circ Physiol 283: H1795-1801.
37. Ray A, Shakya A, Ray BK, (2005) Inflammation-responsive transcription factors SAF-1 and c-Jun/c-Fos promote canine MMP-1 gene expression. Biochim Biophys Acta 1732: 53-61.
38. Cybulsky MI, Movat HZ, Dinarello CA, (1987) Role of interleukin-1 and tumour necrosis factor-alpha in acute inflammation. Ann Inst Pasteur Immunol 138: 505-512.
39. Lee WY, Lockniskar MF, Fischer SM, (1994) Interleukin-1 alpha mediates phorbol ester-induced inflammation and epidermal hyperplasia. FASEB J 8: 1081-1087.
40. Chapman PT, Yarwood H, Harrison AA, Stocker CJ, Jamar F, et al. (1997) Endothelial activation in monosodium urate monohydrate crystal-induced inflammation: in vitro and in vivo studies on the roles of tumor necrosis factor alpha and interleukin-1. Arthritis Rheum 40: 955-965.
41. Maes M, Twisk FN, Kubera M, Ringel K (2011) Evidence for inflammation and activation of cell-mediated immunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Increased interleukin-1, tumor necrosis factor-alpha, PMN-elastase, lysozyme and neopterin. J Affect Disord.
42. van BeijnumJR, van der Linden E, Griffioen AW, (2008) Angiogenic profiling and comparison of immortalized endothelial cells for functional genomics. Exp Cell Res 314: 264-272.
43. Kubota Y, Kleinman HK, Martin GR, Lawley TJ, (1988) Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J Cell Biol 107: 1589-1598.